Pharmaceutical companies fare well with generic drugs

Published: 2011-02-14 06:56:00

Updated: 2011-02-14 06:56:00

Korea’s leading drugmakers saw their flagship generic products’ sales increasing due to robust demand last year, while the revenues in homegrown drugs were still discouraging.

According to Ubist market data, Hanmi Pharmaceutical recorded 41.3 billion won from last year’s sales of Amosartan, fo...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK